Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04841707 · ClinicalTrials.gov registry record · NA
Total-Body Parametric 18F-FDG PET of COVID-19
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT04841707: Completed NA study, sponsored by University of California, Davis.
NCT04841707 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04841707, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary objective is to measure the change between COVID-19 patients and normal subjects; the secondary objective is to measure the change in COVID-19 patients between baseline and 4-month follow up.
Primary Outcome
Evaluating if there is a change in BAB permeability assessed by lung FDG K1 for patients with COVID 19
Interventions
- DEVICE uEXPLORER/mCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2022-07-06 |
| Phase | NA |
What the finished NCT04841707 record still lists
NCT04841707 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which uEXPLORER/mCT is the first listed.
NCT04841707 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04841707 about?
NCT04841707 is a clinical study titled "Total-Body Parametric 18F-FDG PET of COVID-19". The primary objective is to measure the change between COVID-19 patients and normal subjects; the secondary objective is to measure the change in COVID-19 patients between baseline and 4-month follow up.
What is the current status of trial NCT04841707?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2021-05-10. Estimated completion is 2022-07-06.
What interventions are being tested in trial NCT04841707?
The interventions under investigation include: uEXPLORER/mCT (DEVICE).
Who is sponsoring clinical trial NCT04841707?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04841707's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI